HTD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a large equity base provide durable financial flexibility to fund product launches, expand specialty pharmacy networks, and support multiple late‑stage trials without reliance on external financing. This reduces refinancing and covenant risks over the next 2–6 months.
Strong Cash GenerationConsistent cash conversion and sizeable absolute free cash flow provide a stable runway to support commercialization, regulatory filings, and planned pivotal studies. Even with some cooling, positive FCF sustains R&D and launch investments without immediate capital raises.
New Oncology Product With Compelling Survival DataApproval plus a robust survival benefit materially expands the addressable market beyond Cushing's syndrome and creates a durable commercial growth vector. Rapid guideline inclusion and early prescriber uptake support sustainable diversification and potential >$1B oncology revenue over the medium term.
Bears Say
Profitability CompressionSharp margin deterioration reflects elevated launch and operating spend that may persist while scaling oncology and commercialization efforts. Even with revenue growth, compressed margins reduce earnings resilience and could restrain long‑term return metrics and cash flow expansion until operating leverage is realized.
Concentration On Endocrinology RevenueDespite new oncology approvals, near‑term guidance still depends largely on the endocrine franchise and Korlym sales. This product concentration leaves the company exposed to reimbursement, diagnostic uptake, and competitive shifts in a narrow set of indications until oncology revenues scale meaningfully.
Ongoing Legal UncertaintyA revived qui tam action, even without current government intervention, creates protracted litigation risk that can consume management time, increase legal and compliance costs, and create reputational or reimbursement uncertainty—factors that can materially affect operations over many months.
Corcept Therapeutics News
HTD FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is CHF9.84B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 82 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Jul 29, 2026. The company reported CHF0.293 earnings per share for the quarter, beating the consensus estimate of CHF0.02 by CHF0.273.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.64.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 108,098,400 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of CHF0.293 in its last earnings report, beating expectations of CHF0.02. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CH:HTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF110.04 (― Upside)
CHF110.04 (― Upside)
Blogger Sentiment
Bullish
CH:HTD Sentiment 78%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF1.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
HTD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum and meaningful clinical and regulatory progress: strong Q2 financials (+32% revenue growth), a fast and well‑covered Lifyorli launch with survival data supporting uptake, record Korlym prescribing driven by shifting clinical awareness, and multiple near‑term trial readouts. Offsetting these positives are residual regulatory risk for relacorilant (prior CRL, PDUFA Dec 17, 2026), tolerability concerns and mixed statistical significance in early ALS results, and the usual clinical/regulatory execution risks across the pipeline. On balance, the positive financial performance, rapid oncology launch, and pipeline catalysts outweigh the noted risks.View all CH:HTD earnings summariesHTD Stock 12 Month Forecast
Average Price Target
―Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―